Nerve regeneration

From Wikipedia, the free encyclopedia

This article or section needs copy editing for grammar, style, cohesion, tone or spelling. You can assist by editing it now. A how-to guide is available. (May 2008)

This article may require cleanup to meet Wikipedia's quality standards. Please improve this article if you can. (May 2008)

Neuroregeneration refers to the regrowth or repair of the nervous system or its components tissues, cells or cell products. Such mechanisms may include remyelination, generation of new neurons, glia, axons, myelin or synapses. Neuroregeneration differs between the Peripheral Nervous System (PNS) and the Central Nervous System (CNS) by the functional mechanisms and especially, the extent and speed.

When an axon is damaged the distal segment undergoes Wallerian degeneration, losing its myelin sheath. The proximal segment can either die by apoptosis or undergo the chromatolytic reaction, which as an attempt at repair. Repair is made very difficult, as the target of the neuron often atrophies and in the CNS, synaptic stripping occurs as glia foot processes invade the dead synapse.^[1]

Nervous system injuries affect over 90,000 people every year, though function recovery is not guaranteed in most cases ^[2]. It is estimated that spinal cord injuries alone reach 10,000 each year ^[3]. As a result of this high incidence of nervous system injuries, nerve regeneration and repair, a subfield of neural tissue engineering, is becoming a rapidly growing field dedicated to the discovery of new ways to recover nerve functionality after injury. The nervous system is divided into two parts: the central nervous system, which consists of the brain and spinal cord, and the peripheral nervous system, which consists of cranial and spinal nerves along with their associated ganglia. While the peripheral nervous system has an intrinsic ability for repair and regeneration, the central nervous system is for the most part incapable of self-repair and regeneration. There is currently no treatment for recovering human nerve function after injury to the central nervous system ^[4]. In addition, multiple attempts at nerve re-growth across the PNS-CNS transition have not been successful ^[5]. There is simply not enough knowledge yet about regeneration in the central nervous system. And although the peripheral nervous system has the capability for regeneration, much research still needs to be done to optimize the environment for maximum regrowth potential.

Nerve regeneration is important clinically as it is part of the pathogenesis of many diseases, including multiple sclerosis.

Contents 1 Peripheral Nervous System Regeneration 2 Central Nervous System Regeneration 3 Inhibition of Axonal Regrowth 3.1 Chondroitin Sulfate Proteoglycans 3.2 Keratan Sulfate Proteoglycans 3.3 Other inhibitory factors 4 Clinical Treatments 4.1 Autologous Nerve Grafting 4.2 Allografts and Xenografts 4.3 Nerve Guidance Conduit 4.4 Immunisation 5 Notes

[edit] Peripheral Nervous System Regeneration

Neuroregeneration in the PNS occurs to a significant degree.^[6] Axonal sprouts form at the proximal stump and grow until they enter the distal stump. The growth of the sprouts are governed by chemotactic factors secreted from Schwann cells.

Injury to the peripheral nervous system immediately elicits the migration of phagocytic cells, Schwann cells, and macrophages to the lesion site in order to clear away debris such as damaged tissue. When a nerve axon is severed, the end still attached to the cell body is labeled the proximal segment, while the other end is called the distal segment. After injury, the proximal end swells and experiences some retrograde degeneration, but once the debris is cleared, it begins to sprout axons and the presence of growth cones can be detected. The proximal axons are able to regrow as long as the cell body is intact, and they have made contact with the neurolemmocytes in the endoneurial channel. Human axon growth rates can reach 2 mm/day in small nerves and 5 mm/day in large nerves ^[7]. The distal segment, however, experiences Wallerian degeneration within hours of the injury; the axons and myelin degenerate, but the endoneurium remains. In the later stages of regeneration the remaining endoneurial tube directs axon growth back to the correct targets. During Wallerian degeneration, Schwann cells grow in ordered columns along the endoneurial tube, creating a band of Bungner (boB) that protects and preserves the endoneurial channel. Also, macrophages and Schwann cells release neurotrophic factors that enhance re-growth.

[edit] Central Nervous System Regeneration

Unlike peripheral nervous system injury, injury to the central nervous system is not followed by extensive regeneration. It is limited by the inhibitory influences of the glial and extracellular environment. The hostile, non-permissible growth environment is in part created by the migration of myelin-associated inhibitors, astrocytes, oligodendrocytes, oligodendrocyte precursors, and microglia.

The environment within the CNS, especially following trauma, counteracts the repair of myelin and neurons. growth factors are not expressed or re-expressed, for instance the extracellular matrix is lacking laminins. Glial scars rapidly form, and the glia actually produce factors that inhibit remyelination and axon repair, for instance NOGO and NI-35.^{[8][9][10][11]} The axons themselves also lose the potential for growth with age, due to a decrease in GAP 43 expression.

Slower degeneration of the distal segment than that which occurs in the peripheral nervous system also contributes to the inhibitory environment because inhibitory myelin and axonal debris are not cleared away as quickly. All these factors contribute to the formation of what is known as a glial scar, which axons cannot grow across. The proximal segment attempts to regenerate after injury, but its growth is hindered by the environment. It is important to note that central nervous system axons have been proven to regrow in permissible environments; therefore, the primary problem to central nervous system axonal regeneration is crossing or eliminating the inhibitory lesion site. ^[12]

[edit] Inhibition of Axonal Regrowth

Glial scar formation is induced following damage to the nervous system. In the central nervous system, this glial scar formation significantly inhibits nerve regeneration, which leads to a loss of function. Several families of molecules are released that promote and drive glial scar formation. Transforming growth factors B-1 and -2, interleukins, and cytokines all play a role in the initiation of scar formation. The inhibition of nerve regeneration is a result of the accumulation of reactive astrocytes at the site of injury and the up regulation of molecules that are inhibitory to neurite extension outgrowth ^[13]. The up regulated molecules alter the composition of the extracellular matrix in a way that has been shown to inhibit neurite outgrowth extension. This scar formation involves contributions from several cell types and families of molecules, and their roles will be discussed below.

[edit] Chondroitin Sulfate Proteoglycans

In response to scar inducing factors, like those discussed above, astrocytes up regulate the production of chondroitin sulfate proteoglycans. Astrocytes are a predominant type of glial cell in the central nervous system that provide many functions including damage mitigation, repair, and glial scar formation. The RhoA pathway is involved.

Chondroitin sulfate proteoglycans (CSPGs) have been shown to be up regulated in the central nervous system (CNS) following injury. Repeating disaccharides of glucuronic acid and galactosamine, glycosaminoglycans (CS-GAGs), are covalently coupled to the protein core CSPGs. CSPGs have been shown to inhibit regeneration in vitro and in vivo, but the role that the CSPG core protein vs. CS-GAGs had not been studied until recently. A recent study performed experiments to determine the CS-GAGs present in normal uninjured cortex, as well as those present following injury and the resultant mature glial scar. The difference in CS-GAG types and amounts present between the two was then used to study the inhibitory effects of those CS-GAG types up regulated in glial scar on neurite extension. The resulting analysis showed that the GAG profiles of normal cortex and glial scar tissue were significantly different. Glial scar tissue demonstrated an up regulation of chondroitin-4,6-sulfate, chondroitin-2-sulfate, and chondroitin-6-sulfate. On the other hand, uninjured cortical tissue showed most of the CS-GAG to be chondroitin-4-sulfate but also some chondroitin and chondroitin-6-sulfate present.

Using this information, studies were done to quantify the inhibitory effects of CSPGS on neurite outgrowth. All CSPG samples test were shown to be inhibitory to neurite outgrowth. However, CS-E and aggrecan were shown to be the most inhibitory by a large margin, which contained mostly 4,6-sulfated GAG and 4-sulfated GAG respectively. An average neurite length for experiments using these samples was 22 ± 40 µm and 24 ± 44 µm respectively. This is compared to the other averages that were more than ten times these values. ^[14]

The chondroitin sulfate proteoglycans phosphacan and neurocan have also been shown to play a role in glial scar. Phosphacan has been shown to have decreased levels in glial scar when compared to uninjured cortex. This decrease is beneficial to nerve generation because phosphacan has been shown to inhibit neurite extension similarly to the other CSPGs discussed already. Alternatively, neurocan production is up regulated in astrocytes in glial scar when compared to uninjured cortex and astrocytes in primary cell culture conditions. These elevated neurocan levels have been shown to remain elevated 30 days after the initial injury. This implicates neurocan as having a prolonged role in chronic scar.

The inhibition of Rho-kinase (ROCK) with Y27632 has been shown to activate reactive astrocytes and increases their expression of CSPGs. Studies with Y27632 have shown that central nervous system injury sites treated with Y27632 causes an up regulation of glial fibrillary acid protein and neurocan. With in vitro cultures of astrocytes, the same treatment showed an increased expression of CSPGs and a resulting decrease in neurite outgrowth extension. This inhibitory effect was reduced by digesting the CSPG components with chondroitinase-ABC.

NG2 is another type of chondroitin sulfate proteoglycan that is expressed by oligodendrocyte precursor cells. Oligodendrocyte precursor cells are another type of glial cell found in the central nervous system that play a role in glial scar formation. These cell types can develop into a normal oligodendrocyte or a glial fibrillary acidic protein positive astrocyte depending on environmental factors. NG2 is found on the surface of these cells and have been shown to inhibit neurite outgrowth extension as well. These are high molecular weight transmembrane molecules with the largest portion extending into the extracellular space.

Following injury to the central nervous system, NG2 expressing oligodendrocyte precursor cells are seen around the site of injury within 48 hours of the initial injury. The number of NG2 expressing cells continues to increase for the next 3 to 5 days and high levels of NG2 are seen within 7-10 days of the injury. In vitro studies have been done to demonstrate the effect that NG2 levels play on neurite growth inhibition. Notably, neurons would not adhere to substrates solely comprised of NG2, which hints at its inhibitory effects on nerve regeneration. When grown on substrates containing both NG2 and adhesive molecules, neurite extension was shown to be reduced by 40-45% when compared to neurite extension on substrates only containing the adhesive molecules. Furthermore, cultures were created with striped surfaces that alternated NG2 lanes with lanes only containing adhesive molecules. Neurons and axons placed on these striped regions consistently stayed in the lanes without NG2. It is clear then, that the accumulation of NG2 expressing cells at the site of injury creates an extracellular barrier that inhibits axon regrowth into the glial scar area ^[15].

[edit] Keratan Sulfate Proteoglycans

Like the chondroitin sulfate proteoglycans, keratan sulfate proteoglycan (KSPG) production is up regulated in reactive astrocytes as part of glial scar formation. KSPGs have also been shown to inhibit neurite outgrowth extension, limiting nerve regeneration. Keratan sulfate is formed from repeating disaccharide galactose units and N-acetylglucosamines. It is also 6-sulfated. This sulfation is crucial to the elongation of the keratan sulfate chain. A study was done using N-acetylglucosamine 6-O-sulfotransferase-1 deficient mice. The wild type mouse showed a significant up regulation of mRNA expressing N-acetylglucosamine 6-O-sulfotransferase-1 at the site of cortical injury. However, in the N-acetylglucosamine 6-O-sulfotransferase-1 deficient mice, the expression of keratan sulfate was significantly decreased when compared to the wild type mice. Similarly, glial scar formation was significantly reduced in the N-acetylglucosamine 6-O-sulfotransferase-1 mice, and as a result, nerve regeneration was less inhibited. ^[16]

[edit] Other inhibitory factors

Proteins of Oligodendritic or Glial Debris Origin Responsible for Neuroregeneration:

• NOGO –The protein family Nogo, particularly Nogo-A, has been identified as an inhibitor of remyelination in the CNS, especially in autoimmune mediated demyelination, such as found in Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS). Nogo A functions via either its amino-Nogo terminus through an unknown receptor, or by its Nogo-66 terminus through NgR1, p75, TROY or LINGO1. Antagonising this inhibitor results in improved remyelination, as it is involved in the RhoA pathway.^[17][18]

• NI-35 a non-permissive growth factor from myelin.

• MAG –Myelin Associated Glycoprotein acts via the receptors NgR2, GT1b, NgR1, p75, TROY and LINGO11.

• OMgp –Oligodendrocyte Myelin glycoprotein

• Ephrin B3 functions through the EphA4 receptor and inhibits remyelination.^[19]

• Sema 4D functions through the PlexinB1 receptor and inhibits remyelination.^[20]

[edit] Clinical Treatments

[edit] Autologous Nerve Grafting

Currently, autologous nerve grafting or a nerve autograft is known as the gold standard for clinical treatments used to repair large lesion gaps in the peripheral nervous system Nerve segments are taken from another part of the body the donor site and inserted into the lesion to provide endoneurial tubes for axonal regeneration across the gap However this is not a perfect treatment often the final outcome is only limited function recovery Also partial deinnervation is frequently experienced at the donor site and multiple surgeries are required to harvest the tissue and implant it

[edit] Allografts and Xenografts

Variations on the nerve autograft include the allograft and the xenograft. In allografts, the tissue for the graft is taken from another person, the donor, and implanted in the recipient. Xenografts involve taking donor tissue from another species. Allografts and xenografts have the same disadvantages as autografts, but in addition, tissue rejection from immune responses must also be taken into account. Often immunosuppression is required with these grafts. Disease transmission also becomes a factor when introducing tissue from another person or animal. Overall, allografts and xenografts do not match the quality of outcomes seen with autografts, but they are necessary when there is a lack of autologous nerve tissue.

[edit] Nerve Guidance Conduit

Because of the limited functionality received from autografts, the current gold standard for nerve regeneration and repair, recent neural tissue engineering research has focused on the development of bioartificial nerve guidance conduits in order to guide axonal regrowth. The creation of artificial nerve conduits is also known as entubulation because the nerve ends and intervening gap are enclosed within a tube composed of biological or synthetic materials ^[21].

[edit] Immunisation

A direction of research is towards the use of drugs that target remyelinating inhibitor proteins, or other inhibitors or neuroregeneration 3. Possible strategies include vaccination against these proteins (active immunisation), or treatment with previously created antibodies (passive immunisation). These strategies appear promising on animal models with experimental autoimmune encephalomyelitis (EAE), a model of MS.^[22]

Monoclonal antibodies have also been used against inhibitory factors such as NI-35 and NOGO.^[23]

[edit] Notes